

1 **Modeling and Interpreting Patient Subgroups in Hospital Readmission:**  
2 **Visual Analytical Approach**

3 Suresh K. Bhavnani, Ph.D.,<sup>1,2§</sup> Weibin Zhang, Ph.D.,<sup>1</sup> Shyam Visweswaran, M.D., Ph.D.,<sup>3,4</sup>  
4 Mukaila Raji, M.D., M.S., F.A.C.P.,<sup>5</sup> Yong-Fang Kuo, Ph.D.<sup>1</sup>

5  
6 <sup>1</sup>School of Public and Population Health, University of Texas Medical Branch, Galveston, TX, USA

7 <sup>2</sup>Institute for Translational Sciences, University of Texas Medical Branch, Galveston, TX, USA

8 <sup>3</sup>Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA

9 <sup>4</sup>Intelligent Systems Program, University of Pittsburgh, Pittsburgh, PA, USA

10 <sup>5</sup>Division of Geriatric Medicine, Department of Internal Medicine, University of Texas Medical Branch Galveston, TX, USA

11

12

13 <sup>§</sup>Corresponding author

14 Suresh K. Bhavnani, Ph.D., M.Arch., FAMIA

15 School of Public and Population Health

16 Institute for Translational Sciences

17 University of Texas Medical Branch

18 301 University Blvd

19 Galveston, TX, USA

20 email: subhavna@utmb.edu

## 21 **ABSTRACT**

### 22 **Background**

23 A primary goal of precision medicine is to identify patient subgroups and infer their underlying disease processes,  
24 with the aim of designing targeted interventions. However, few methods automatically identify both patient  
25 subgroups and their co-occurring characteristics simultaneously, measure their significance, and visualize the  
26 results. Such methods could enhance the interpretability of patient subgroups, and inform the design of  
27 classification and predictive models.

### 28 **Objectives**

29 To analyze patient subgroups in hospital readmitted patients using a three-step modeling approach. (1) *Visual*  
30 *analytical* modeling to automatically identify patient subgroups and their co-occurring comorbidities, and  
31 determine their statistical significance and clinical interpretability. (2) *Classification* modeling to classify patients  
32 into subgroups and measure its accuracy. (3) *Prediction* modeling to predict a patient's risk of readmission and  
33 compare its accuracy with and without patient subgroup information.

### 34 **Methods**

35 We extracted 2013-2014 Medicare data related to hospital readmission in three conditions: chronic obstructive  
36 pulmonary disease (COPD), congestive heart failure (CHF), and total hip/knee arthroplasty (THA/TKA). For each  
37 condition, we extracted cases defined as patients readmitted within 30 days of hospital discharge, and controls  
38 defined as patients not readmitted within 90 days of discharge, matched by age, gender, race, and Medicaid  
39 eligibility (n[COPD]=29,016, n[CHF]=51,550, n[THA/TKA]=16,498). These data were analyzed using: (1) bipartite  
40 networks to identify patient subgroups based on frequently co-occurring high-risk comorbidities; (2) multinomial  
41 logistic regression to classify patients into subgroups; and (3) hierarchical logistic regression to predict the risk  
42 of hospital readmission using subgroup membership, compared to standard logistic regression without subgroup  
43 membership.

### 44 **Results**

45 In each condition, the visual analytical model identified patient subgroups that were statistically significant  
46 ( $Q=0.17, 0.17, 0.31$ ;  $P<.001, <.001, <.05$ ), were significantly replicated ( $RI=0.92, 0.94, 0.89$ ;  $P<.001, <.001, <.01$ ),  
47 and were clinically meaningful to clinicians. (2) In each condition, the classification model had high accuracy in  
48 classifying patients into subgroups (mean accuracy=99.60%, 99.34%, 99.86%). (3) In two conditions (COPD,  
49 THA/TKA), the hierarchical prediction model had a small but statistically significant improvement in  
50 discriminating between the readmitted and not readmitted patients as measured by net reclassification  
51 improvement ( $NRI=.059, .11$ ), but not as measured by the C-statistic or integrated discrimination improvement  
52 (IDI).

### 53 **Conclusions**

54 While the visual analytical models identified statistically and clinically significant patient subgroups, the results  
55 pinpoint the need to analyze subgroups at different levels of granularity for improving the interpretability of  
56 intra- and inter-cluster associations. The high accuracy of the classification models reflects the strong separation  
57 of the patient subgroups despite the size and density of the datasets. Finally, the small improvement in predictive  
58 accuracy suggests that comorbidities alone were not strong predictors for hospital readmission, and the need  
59 for more sophisticated subgroup modeling methods. Such advances could improve the interpretability and  
60 predictive accuracy of patient subgroup models for reducing the risk of hospital readmission and beyond.

## 61 INTRODUCTION

### 62 Background

63 A wide range of studies [1-9] on topics ranging from molecular to environmental determinants of health have  
64 shown that most humans tend to share a subset of characteristics (e.g., comorbidities, symptoms, genetic  
65 variants), forming distinct patient subgroups. A primary goal of precision medicine is to identify such patient  
66 subgroups and infer their underlying disease processes to design interventions targeted to those processes [2,  
67 10]. For example, recent studies in complex diseases such as breast cancer [3, 4], asthma [5-7] and COVID-19  
68 [11] have revealed patient subgroups, each with different underlying mechanisms precipitating the disease, and  
69 therefore each requiring different interventions.

70 A critical requirement for designing such interventions is the clinical interpretability of patient subgroups. Such  
71 interpretability requires clinicians to understand (a) how characteristics (e.g., comorbidities, symptoms, genetic  
72 variants) frequently and significantly co-occur across patients, and (b) the risk for adverse outcomes (e.g.,  
73 mortality, hospital readmission) of patient subgroups that have those co-occurrences. An integration of the co-  
74 occurrence of characteristics, with the risk of outcomes in patient subgroups, is critical to infer the disease  
75 processes underlying each patient subgroup, and to design precision interventions targeted to those patient  
76 subgroups. However, few methods automatically identify both patient subgroups and their co-occurring  
77 characteristics simultaneously, which is important for measuring the risk for adverse outcomes and inferring  
78 their mechanisms. Such integrated methods could enhance the interpretability of patient subgroups by clinicians  
79 for designing interventions, and for informing the design of classification and predictive models that provide  
80 clinical decision support.

81 To address this need, we used a visual analytical method to identify and analyze patient subgroups in hospital  
82 readmitted patients. While we have previously demonstrated [12] the use of visual analytics to identify patient  
83 subgroups and their characteristics in hospital readmission, here we explore how the approach generalizes  
84 across three hospital readmission conditions and its use in classification and predictive modeling. This was done  
85 through an analytical framework for Modeling and Interpreting Patient Subgroups (MIPS) which used a three-  
86 step modeling approach: (1) *Visual analytical* modeling through bipartite networks to automatically identify  
87 patient subgroups and their co-occurring characteristics, and determine their statistical significance and clinical  
88 interpretability. (2) *Classification* modeling through multinomial logistic regression to classify patients into  
89 subgroups. (3) *Prediction* modeling through logistic regression with and without subgroup information to predict  
90 the risk of hospital readmission. Application of the MIPS analytical framework to three datasets helped pinpoint  
91 methodological and data limitations in our approach, which provided implications for improving the  
92 interpretability of patient subgroups in large and dense datasets, and for the design of clinical decision support  
93 systems to prevent adverse outcomes such as hospital readmissions.

### 94 Current Approaches for Identifying Patient Subgroups

95 A patient subgroup is a subset of patients drawn from a population (e.g., older adults) that share one or more  
96 characteristics (e.g., renal failure and diabetes). Patients have been divided into subgroups by using (a)  
97 investigator-selected variables such as race for developing hierarchical regression models [13], or assigning  
98 patients to different arms of a clinical trial, (b) existing classification systems such as the Medicare Severity-  
99 Diagnosis Related Group (MS-DRG) [14] to assign patients into a disease category for purposes of billing, and (c)  
100 computational methods such as classification [15-17] and clustering [5, 18] to discover patient subgroups from  
101 data (also referred to as *subtypes* or *phenotypes* depending on the condition and variables analyzed).

102 One of the simplest computational methods to identify patient subgroups is by enumerating conjunctions  
103 (identify all pairs, all triples, etc.) of variables such as comorbidities [19] that co-occur across patients and then  
104 examining the most prevalent subgroups. While such approaches are intuitive, they can lead to a combinatorial  
105 explosion (e.g., enumerating combinations of the 31 Elixhauser comorbidities would lead to  $2^{31}$  or 2147483648  
106 combinations), and most combinations do not incorporate the full range of comorbidities (e.g., the most  
107 frequent pair of comorbidities ignores other comorbidities that might exist in the profile of patients with that  
108 pair). Other approaches use *unipartite* clustering methods [17, 18] (e.g., clustering patients or comorbidities, but

109 not both together) such as k-means and hierarchical clustering; and dimensionality-reduction methods such as  
110 principal component analysis (PCA) [17] to identify *principal components* to define a reduced dimensionality  
111 plane on which patients or comorbidities are projected, which are then clustered using unipartite methods such  
112 as k-means (together referred to as spectral clustering).

113 However, because these methods are unipartite, there is no agreed-upon method to identify the patient  
114 subgroup defined by a cluster of characteristics, or vice-versa, which substantially reduces the interpretability of  
115 the results. Furthermore, such methods have well-known limitations, including (a) requiring a user-defined input  
116 for a similarity measure (e.g., Jaccard distance) to calculate the similarity between pairs of patients based on  
117 their profiles, or pairs of characteristics based on how their co-occurrence across patients, (b) requiring a user-  
118 defined input for the expected number of clusters, and (c) the absence of a quantitative measure to measure  
119 the quality of the clustering, critical for measuring the statistical significance of the clustering.


120 More recent *bipartite* network analytical  
121 methods [20] have attempted to address  
122 these limitations by automatically identifying  
123 biclusters [18, 21, 22] (e.g., clustering of  
124 patients and comorbidities simultaneously).  
125 A network consists of nodes and edges;  
126 nodes represent one or more types of  
127 entities (e.g., patients or comorbidities), and  
128 edges between the nodes represent a  
129 specific relationship between the entities.

130 Figure 1A shows a unipartite network, where  
131 nodes are of the same type (often used to  
132 analyze co-occurrence of comorbidities [23]).  
133 In contrast, Figure 1B shows a bipartite  
134 network where nodes are of two types, and  
135 edges exist only between different types  
136 such as between patients (circles) and  
137 comorbidities (triangles). This approach uses

138 bipartite modularity maximization [20, 24-26], a graph-theoretic  
139 approach to (a) quantitatively output the number, size, and statistical significance [18, 27] of biclusters  
140 (consisting of a patient subgroup and its most frequently co-occurring comorbidities), and (b) visualize those  
141 biclusters using layout algorithms [28, 29] to enable their clinical interpretation [11, 12, 30-36]. As shown in Fig.  
142 1C, a bipartite visualization could enable clinicians to inspect the bicluster associations, infer potential  
143 mechanisms in each patient subgroup, and design targeted interventions. Our prior use of bipartite networks  
144 have enabled three types of discoveries related to subgroups: (1) *novel subtypes* (e.g., in asthma [33]); (2)  
145 *frequency of known subtypes* in a new condition (e.g., in COVID-19 [11]), and (3) *risk of subtypes* for adverse  
146 outcomes (e.g., in hip fracture hospital readmission [12]). Furthermore, the above subgroups could be used to  
147 train classifiers for classifying a new patient into a subgroup, and to build predictive models that leverage such  
148 patient subgroups to predict an outcome in a new patient.

## 148 Leveraging Patient Subgroups in Predictive Modeling

149 Patient subgroups are leveraged in predictive modeling using two common approaches [37] that trade-off  
150 simplicity with accuracy: (1) *Hierarchical Modeling* adds subgroup information (e.g., a subgroup membership  
151 variable specifying to which subgroup a patient belongs, predicted by a classifier) to a Standard Model without  
152 subgroup membership information to improve accuracy. However, while this approach is simple, it potentially  
153 trade-offs accuracy as the model's parameters (e.g., slope and intercept of a regression model) are fixed for all  
154 patients, regardless of subgroup membership. (2) *Subgroup-Specific Modeling* develops multiple models, one  
155 for each subgroup, allowing each model to have different model parameters, potentially improving accuracy.  
156 However, this improved accuracy trade-offs simplicity as the evaluation requires several additional steps: build  
157 multiple predictive models, predict the outcomes for each patient using the appropriate model (predicted by a



**Fig. 1.** Comparison between a unipartite (A) and a bipartite network representation (B), and how a bipartite network analysis can automatically identify biclusters containing patient subgroups and their most frequently co-occurring comorbidities (C).

158 classifier), aggregate the accuracy of predictions across all patients, and compare it to the predictive accuracy of  
159 all patients generated from the Standard Model. Given this complexity, we used the simpler Hierarchical  
160 Modeling approach as a preliminary step for leveraging patient subgroups.

## 161 **The Need for Automatic Identification of Patient Subgroups in Hospital Readmission**

162 An estimated one in five elderly patients (over 2.3 million Americans) is readmitted to a hospital within 30-days  
163 after being discharged [38]. While many readmissions are unavoidable, an estimated 75% of readmissions are  
164 unplanned and mostly preventable [39], imposing a significant burden in terms of mortality, morbidity, and  
165 resource consumption. Across all conditions, unplanned readmissions cost almost \$17 billion annually in the US  
166 [39], making them an ineffective use of costly resources, and therefore closely scrutinized as a marker for the  
167 poor quality of care by organizations such as the Centers for Medicare & Medicaid Services (CMS) [40].

168 To address this epidemic of hospital readmission, CMS sponsored the development of models to predict the  
169 patient-specific risk of readmission in specific index conditions such as chronic obstructive pulmonary disease  
170 (COPD) [41], congestive heart failure (CHF) [42], and hip/knee arthroplasty (THA/TKA) [43]. These models have  
171 two characteristics that are pertinent to the current study:

- 172 1. Inclusion of Comorbidities as Independent Variables. The independent variables (predictors) in the CMS  
173 models were prior comorbidities (as recorded in Medicare claims data), and demographics (age, gender, and  
174 race). The use of comorbidities was based on extensive literature showing the critical role comorbidities play  
175 in increasing the risk for adverse outcomes in older adults [38]. For example, almost two-thirds of older  
176 adults have two or more comorbid conditions, resulting in a heightened risk for adverse health outcomes  
177 such as hospital readmission and mortality [44]. Furthermore, multiple comorbidities often do not act  
178 independently, but rather interact with each other, resulting in processes that can precipitate readmission  
179 [45]. For example, due to the systemic nature of renal disease, a hip fracture patient with congestive heart  
180 failure and renal failure is at a higher risk of renal failure exacerbation, precipitating a hospital readmission,  
181 compared to one who only had renal failure [12]. To enable a head-to-head comparison with the CMS  
182 predictive models, we used the same independent variables for our predictive models.
- 183 2. Exclusion of Patient Subgroups. None of the CMS models used information related to patient subgroups.  
184 Therefore, while such models provide the risk of readmission for an individual patient, they do not leverage  
185 the existence of patient subgroups known to be present among patients with hospital readmission [12]. Such  
186 patient subgroups could be used in hierarchical regression models to potentially achieve higher predictive  
187 accuracy. Furthermore, while the primary focus of the CMS models was on predicting the risk of readmission  
188 of a patient, they provide little clinical guidance for the design of clinical interventions to address that risk.  
189 In contrast, if a patient belongs to a previously-identified patient subgroup with a comorbidity profile (often  
190 referred to as a phenotype), such information could be leveraged to classify patients into the best-fitting  
191 phenotype, and then to use that classification as a starting point to design clinical interventions targeted to  
192 the patient.

193 Here we demonstrate the development and use of an analytical framework for Modeling and Interpreting  
194 Patient Subgroups (MIPS) by using a three-step modeling approach: (1) bipartite networks to automatically  
195 identify subgroups of readmitted patients and their frequently co-occurring comorbidities, (2) classifiers to  
196 classify patients into a best-fitting subgroup, and (3) hierarchical predictive models which leverage the subgroup  
197 information to predict each patient's risk of readmission. This analytical framework was tested across three  
198 index conditions where readmission frequently occurs.

## 199 **METHOD**

### 200 **Overview of Method**

201 Fig. 2 provides a conceptual description of the data inputs and outputs from the three-step modeling in MIPS.  
202 As shown, the visual analytical model identifies the patient subgroups, and visualizes them through a network.  
203 The classification model predicts subgroup membership for cases and controls, and uses it to measure the risk  
204 of readmission within each subgroup based on its proportion of cases. This risk information is juxtaposed with

205 the visualization to enable clinicians  
206 interpret the readmitted patient  
207 subgroups. Finally, the predictive model  
208 uses the subgroup membership  
209 assignment of cases and controls to  
210 predict the readmission risk of a patient.

## 211 Data Description


212 Study population. We analyzed patients  
213 hospitalized for chronic obstructive  
214 pulmonary disease (COPD), congestive  
215 heart failure (CHF), and total hip/knee  
216 arthroplasty (THA/TKA). We selected  
217 these three index conditions because: (a)  
218 hospitalizations for each of these  
219 conditions are highly prevalent in older  
220 adults [38]; (b) hospitals report very high  
221 variations in their readmission rates [38];  
222 and (c) there exist well-tested  
223 readmission prediction models for each of  
224 these conditions that did not consider  
225 patient subgroups [41-43, 46, 47].

226 For each index condition, we used the  
227 same inclusion and exclusion criteria used  
228 to develop the CMS models, but with the  
229 most recent years (2013-2014) provided  
230 by Medicare when we started the project.  
231 We used 100% of the 30-day readmitted  
232 patients in 2013 and 2014 Medicare claims data, from which we extracted all patients that were admitted to an acute care hospital on or after July 2013-August 2014 with a principal diagnosis of the index condition, were 66 years of age or older, and were enrolled in both Medicare parts A and B fee-for-service plans in the 6 months before admission. Furthermore, we excluded patients who were transferred from other facilities, died during the hospitalization, or transferred to another acute care hospital. Similar to the CMS models, we selected the first admission for patients with multiple admissions during the study period, and did not use Medicare Part D (related to prescription medications).

239 Next, we extracted 100% controls who were not readmitted for at least 90 days since discharge. CMS uses this 90-day window of no re-admittance to ensure that the controls are substantially free of complications that result in readmission during this period [48, 49]. A small percentage (0.8%) of Medicare patients had “unknown race” for the Race attribute, so we grouped “unknown race” and “other race” and ensured that there was an equal number of them in the cases and control datasets. The low rate of missing data on race had too low a risk for bias to warrant a sensitivity analysis. Appendix-1 shows the detailed inclusion and exclusion criteria used to extract cases and controls for COPD, CHF, and THA/TKA, and the respective numbers of patients extracted at each step, in addition to the International Classification of Diseases, Ninth Version codes (ICD-9) codes for each of the three index conditions selected for analysis. Each modeling method used appropriate subsets of the above data described in the sections below.

249 Variables. The dependent variable (outcome) was whether a patient with an index admission (COPD, CHF, THA/TKA) had an unplanned readmission to an acute-care hospital within 30 days of discharge, as was recorded in the MEDPAR file (inpatient claims) in the Medicare database.

## Modeling and Interpreting Patient Subgroups (MIPS)



**Fig. 2.** Inputs and outputs for the three-step modeling in MIPS. The visual analytical model quantitatively identifies the patient subgroups, and visualizes them using a bipartite network. The classification model predicts subgroup membership of cases and controls in addition to the risk of each subgroup, which is juxtaposed with the visualization to enable clinicians to qualitatively interpret the readmission subgroups. The predictive model uses subgroup membership, comorbidities, and demographics to predict the risk of a new patient for being readmitted.

252 The independent variables included comorbidities, and patient demographics (age, gender, race). Comorbidities  
 253 common in older adults were derived from three established comorbidity indices: Charlson Comorbidity Index  
 254 (CCI) [50], Elixhauser Comorbidity Index (ECI) [51], and the Center for Medicare and Medicare Services Condition  
 255 Categories (CMS-CC) used in the CMS readmission models [52] (the variables in the CMS models varied across  
 256 the index conditions). As these indices had overlapping comorbidities, we derived a union of them, which was  
 257 verified by the clinician stakeholders. They recommended that we also include the following additional variables  
 258 as they were pertinent to each index condition: COPD (history of sleep apnea, mechanical ventilation); CHF  
 259 (history of coronary artery bypass graft surgery); THA/TKA (congenital deformity of the hip joint, post-traumatic  
 260 osteoarthritis). For each patient in our cohort, we extracted the above comorbidities and variables from the  
 261 physicians, outpatient, and inpatient Medicare claims data in the 6 months before (to guard against miscoding),  
 262 and on the day of the index admission.

## 263 Analytical and Evaluation Approach

264 Overview of the MIPS Framework. Table 1 provides a summary of the inputs and outputs of the three-step  
 265 modeling approach in the MIPS framework, which was applied across the three index conditions.

266 Visual Analytical Modeling. The data used to build the visual analytical model consisted of 100% cases, and an  
 267 equal number of 1:1 matched controls extracted by randomly selecting a control without replacement to match  
 268 each case based on age, gender, race/ethnicity, and Medicaid eligibility [53]. The resulting dataset was divided  
 269 randomly into a training (50%) and replication (50%) dataset (we use the term *replication* to avoid confusion  
 270 with the term *validation* typically used in classification and prediction models). We used a bipartite network to

Model	Inputs	Outputs
<b>1. Visual Analytical</b> (Bipartite Network Analysis)	<ul style="list-style-type: none"> <li>• <b>Training Dataset:</b> 50% random sample of 100% cases, and an equal number of 1:1 matched controls (used only for feature selection)</li> <li>• <b>Replication Dataset:</b> 50% random sample of 100% cases and equal number of 1:1 matched controls</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Model Training</b> <u>Feature Selection:</u> Set of comorbidities univariably significant in both the training and replication datasets <u>Biclustering:</u> Modularity (degree of biclusteredness) and its significance, number of biclusters (subgroups), and their patient and comorbidity members in the training and replication datasets</li> <li>• <b>Model Replication</b> <u>Comorbidity Co-Occurrence:</u> Rand Index (degree of replication), and its significance to measure replicability of comorbidity co-occurrence</li> <li>• <b>Model Interpretation</b> <u>Visualization:</u> Layout of the bipartite network juxtaposed with risk of individual comorbidities and subgroups <u>Clinical Significance:</u> Interpretation by clinicians for face validity of patient subgroups based on comorbidity co-occurrence, leading to inference of mechanisms precipitating readmission, and interventions</li> </ul>
<b>2. Classification</b> (Multinomial Logistic Regression)	<ul style="list-style-type: none"> <li>• <b>Training Dataset:</b> Random sample of 75% cases, with bicluster membership</li> <li>• <b>Internal Validation Dataset:</b> Random sample of 25% of cases (with subgroup membership used to validate the model)</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Model Training</b> <u>Subgroup Membership:</u> Probability of membership of each case to each subgroup (soft labels), with the highest used to determine subgroup membership (hard labels)</li> <li>• <b>Model Internal Validation</b> <u>Internal Validation:</u> Accuracy of classification model based on hard labels</li> <li>• <b>Model Application</b> <u>Classification:</u> Subgroup classification of 100% cases and 100% controls <u>Subgroup Risk:</u> Proportion of cases in each subgroup</li> </ul>
<b>3. Prediction</b> (Binary Logistic Regression, and Hierarchical Binary Logistic Regression)	<ul style="list-style-type: none"> <li>• <b>Training Dataset:</b> Random samples of 75% of 100% cases and controls, with subgroup membership</li> <li>• <b>Internal Validation Dataset:</b> Random sample of 25% of cases and controls (with case/control labels used to validate the model)</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Model Training</b> <u>Predicted Risk:</u> Each patient's probability of being readmitted.</li> <li>• <b>Model Internal Validation</b> <u>Internal Validation:</u> C-statistic (discrimination), and calibration-in-the-large and calibration slope (calibration)</li> <li>• <b>Model Comparison</b> <u>Accuracy:</u> Net Reclassification Improvement (NRI) and Integrated Discrimination Improvement (IDI)</li> </ul>

**Table 1.** Inputs used to train and replicate/validate the three models, and the analytical outputs they produced.

- 271 model the cases (30-day readmitted patients) and significant comorbidities in each index condition using the  
272 following steps:
- 273 A. *Model Training*. The training of the bicluster network model consisted of the following two steps:
- 274 I. *Feature Selection*. Given the large number of patients and comorbidities in the dataset, we used feature  
275 selection to identify comorbidities with the strongest signal and therefore interpretability for readmission  
276 using the following steps: (1) excluded comorbidities with prevalence less than 1% (as is commonly done  
277 in studies to reduce noise [54]); (2) selected significant comorbidities in the training dataset based on a  
278 2-way interaction test using odds ratio (OR) with directionality, and correcting for multiple testing using  
279 Bonferroni, and (3) tested the surviving comorbidities for replication in the replication dataset, and  
280 selected those that were significant in both datasets. Appendix-2 shows the number of comorbidities,  
281 and variables that were included in the analysis for each of the three index conditions. The above feature  
282 selection generated a single set of significant and replicated comorbidities used for the following bipartite  
283 network analysis.
- 284 II. *Biclustering*. We used bipartite networks on the training dataset to analyze heterogeneity in readmission  
285 using the following steps. (1) Removed all cases that did not have any comorbidities (as the modularity  
286 maximization algorithm will trivially put disconnected nodes into a separate cluster). (2) Represented the  
287 cases (30-day readmitted patients in the training dataset) and their significant and replicated  
288 comorbidities (selected in Step A) as a bipartite network. As shown in Fig. 1, the nodes represented cases  
289 or comorbidities, and edges represented which case had which comorbidity. (3) Used a bipartite  
290 modularity maximization algorithm to identify the number of biclusters, their boundaries, and degree of  
291 biclusteredness using modularity. Modularity is defined as the fraction of edges falling within a cluster,  
292 minus the expected fraction of such edges in a network of the same size with randomly assigned edges  
293 [20]. Modularity ranges from -0.5 to +1, with values >0 indicating biclustering that is higher than can be  
294 expected by chance. We used the bipartite version of modularity [55, 56] to find biclusters in the network.  
295 (4) Measured the significance of the bicluster modularity by comparing it to a distribution of the same  
296 quantity generated from 1000 random permutations of the network, by preserving the network size  
297 (number of nodes) and the network density (number of edges).
- 298 B. *Model Replication*. Repeated the above biclustering steps 1-4 to identify subgroups in the replication  
299 dataset, and compared the comorbidity co-occurrence in the training dataset, to that in the replication  
300 dataset using the Rand index (RI) [57]. RI measures the proportion of comorbidity pairs that co-occurred and  
301 did not co-occur in a cluster in the training and replication datasets (where 0=no inter-network cluster  
302 similarity, and 1=total inter-network cluster similarity). The significance of RI was measured by comparing it  
303 to a distribution of the same quantity generated from 1000 random permutations of the training and  
304 replication networks. All tests of statistical significance in Steps A and B were 2-sided.
- 305 C. *Model Interpretation*. The model interpretation consisted of the following steps:
- 306 I. *Visualization*. We used the following steps to visualize the network generated from the training dataset.  
307 (1) Used *Fruchterman-Reingold* (FR) [58], a force-directed algorithm to lay out the bipartite network.  
308 This layout algorithm pulls together nodes that are strongly connected, and pushes apart nodes that are  
309 not. This results in nodes with a similar pattern of connections to be placed close to each other in  
310 Euclidean space, and those that are dissimilar are pushed apart. (2) As the FR algorithm often cannot  
311 entirely separate clusters in large and dense networks, the network layout needs to be visually enhanced  
312 before it is interpretable by clinician stakeholders. Therefore, we used the *ExplodeLayout* algorithm [28,  
313 29] to separate the biclusters to reduce their visual overlap. This algorithm preserves the distances of  
314 nodes within a bicluster, but increases the distance of nodes between clusters to improve  
315 interpretability. (3) Juxtaposed the risk of readmission with the network visualization (in response to a  
316 request from the clinical stakeholders). This was done by (a) displaying comorbidity labels with their  
317 univariable ORs for readmission (measured in Step A) ranked by their odds ratios (ORs) for each  
318 subgroup, and (b) measuring the readmission risk for each patient subgroup based on the full case-



319 control population (explained in more detail in the section on predictive modeling), and juxtaposing it  
320 with the respective subgroup.

321 II. *Clinical Interpretation.* We used the following steps to solicit clinical interpretations of the above  
322 bipartite network. (1) Recruited a pulmonologist specializing in COPD and hospital readmission to  
323 interpret the COPD results, and a geriatrician with expertise in treating older adults in CHF and THA/TKA  
324 to interpret the respective results. (2) Requested each clinician stakeholder to interpret the patient  
325 subgroups, their mechanisms, and potential interventions to reduce the risk for readmission.

326 Classification Modeling. As shown in the bipartite network example in Fig. 1, the biclusters identified through  
327 the modularity maximization algorithm contain patient subgroups and their *most frequently* co-occurring  
328 comorbidities with respect to other patients in the network. However, there are often many edges between  
329 biclusters, revealing that many patients within a bicluster have comorbidities that exist in other biclusters. As is  
330 true for most partitioning cluster methods, including modularity, membership of a new patient to each bicluster  
331 is therefore *probabilistic*. The classification of a patient into a cluster is therefore not defined by the *inclusion or*  
332 *exclusion of comorbidities* (e.g., hypertension and diabetes), but rather by the *probability* of being in a patient  
333 subgroup. Patients are therefore similar or different, not just in a handful of carefully-selected comorbidities  
334 while ignoring others, but based on *all* of their recorded comorbidities. This overall profile of patients reflects  
335 the reality of comorbid conditions.

336 To model the above complexity, we used multinomial logistic regression [17] to develop classification models in  
337 each index condition. This approach has the advantage of generating probabilities (“soft labels”) for a patient to  
338 belong to each patient subgroup. The models were trained, internally validated, and then applied to generate  
339 information for the other two modeling methods, as described below:

340 A. *Model Training.* The data used to build the classification model consisted of the training dataset and  
341 subgroup membership from the visual analytical model. We trained a multinomial logistic regression model  
342 using the above data, with independent variables that included comorbidities identified through feature  
343 selection done for the visual analytical modeling. Accuracy of the trained model was measured by calculating  
344 the percentage of times the model correctly classified the cases into the subgroups, using the highest  
345 predicted probability across the subgroups (“hard labels”).

346 B. *Model Internal Validation.* To internally validate the classifier, we randomly split the above data into training  
347 (75%) and testing (25%) datasets, 1000 times. For each iteration, we trained a model using the training  
348 dataset, and measured its accuracy on the testing dataset. This was done by predicting the subgroup  
349 membership using the highest predicted probability among all the subgroups. The overall predicted accuracy  
350 was then estimated by calculating the mean accuracy across the 1000 models.

351 C. *Model Application.* Using the 100% cases, in addition to the 100% controls from July 2013-August 2014  
352 (representing the entire Medicare population of each index condition from those years), we generated the  
353 following two types of information for use in the other models. (1) Used the classifier trained in Step A above,  
354 to classify 100% cases and 100% controls into a subgroup. This information was used by the subsequent  
355 predictive modeling. (2) While the visual analytical model used the 1:1 matched controls for feature  
356 selection, this cohort did not represent the entire population. Therefore, to accurately measure the  
357 subgroup risk, we used the entire case-control population classified into the subgroups (as described in the  
358 above step), and measured the proportion of cases in each subgroup. Furthermore, as requested by the  
359 clinicians, we juxtaposed these subgroup risks next to the respective subgroups in the bipartite network  
360 visualization, to improve their interpretability.

361 Predictive Modeling. The data used to build the predictive models consisted of 100% cases and 100% controls,  
362 in addition to their subgroup membership generated from the above classification models. These data were  
363 randomly split into a training (75%) and validation (25%) dataset. The predictive models were trained, internally  
364 validated, and compared for predictive accuracy, as described below:

- 365 A. *Model Training*. We used the training dataset to train a Standard Model (binary logistic regression without  
366 subgroup membership similar to the CMS models), and a Hierarchical Model (binary logistic regression with  
367 subgroup membership), with 30-day unplanned readmission (yes vs. no) as the outcome. Independent  
368 variables for both models included comorbidities identified through the feature selection in each index  
369 condition (see Appendix-2), and demographics. The Hierarchical Model additionally included subgroup  
370 membership.
- 371 B. *Model Internal Validation*. We used the validation dataset to internally validate the models through the  
372 following two measures:
- 373 I. Discrimination (model's ability to distinguish readmitted patients from those not readmitted) was  
374 measured using the C-statistic, which is identical to the area under the receiver operating characteristic  
375 (ROC) curve. Model discrimination was examined using box plots to show the average risk prediction for  
376 patients with and without readmission.
- 377 II. Calibration (model's agreement of the predicted probabilities with the observed risk) was measured using  
378 calibration-in-the-large, and calibration slope, which was examined through a calibration plot showing the  
379 proportion of patients actually admitted, versus deciles of predicted probability of having readmission.  
380 Good calibration is when calibration-in-the-large is close to zero, and the calibration slope is close to one.  
381 Since the large sample size overpowered the study, we did not measure the calibration based on statistical  
382 significance (e.g., *P* values of the Hosmer-Lemeshow and calibration indices).
- 383 C. *Model Comparisons*. We used the chi-squared test to compare the C-statistic of the Standard Model to that  
384 of the Hierarchical Model. We also measured the C-statistic of the Standard Model applied to each subgroup  
385 separately. This enabled examination of how the Standard Model performed on patient subgroups to  
386 identify, for example, which subgroups underperformed when using the current Standard Model.
- 387 Because the above models used the feature selection step to select comorbidities for use as independent  
388 variables, they differed from those used in the published CMS models. Therefore, to perform a head-to-head  
389 comparison with the published CMS models, we additionally developed a logistic regression model using  
390 independent variables that were identical to the published CMS model (CMS Standard Model), which was  
391 compared to the same model that included subgroup membership (CMS Hierarchical Model). We used the  
392 chi-squared test to compare the C-statistic of the CMS Standard Model to that from the CMS Hierarchical  
393 Model, in addition to the following measures of model accuracy:
- 394 I. Net Reclassification Improvement (NRI) measured the proportion of patients whose predicted probability  
395 of readmission improved with reference to actual readmission status. We used two NRI statistics: (a)  
396 categorical NRI, which predicted readmission probabilities divided into 10 sequential categories ranging  
397 from 0-1, with improvement requiring a shift between categories; and (b) continuous NRI which is based  
398 on the proportions of patients with any improved predicted probability of readmission, regardless of the  
399 size of that improvement.
- 400 II. Integrated Discrimination Improvement (IDI) measured the difference in the average improvement in  
401 predicted risks between the CMS Standard Model and the CMS Hierarchical Model.

## 402 **RESULTS**

### 403 **Data**

404 Table 2 provides a summary of the number of cases and/or controls used to develop the three models in each  
405 condition.

### 406 **Visual Analytical Modeling**


407 The visual analytical modeling of readmitted patients in all three index conditions produced statistically and  
408 clinically significant patient subgroups and their most frequently co-occurring comorbidities, which were  
409 significantly replicated. Results from each condition are described below:

410 **COPD.** The inclusion and exclusion  
 411 selection criteria (see Appendix-1)  
 412 resulted in a training dataset  
 413 (n=14,508 matched case/control  
 414 pairs, of which 51 patient pairs with  
 415 no dropped comorbidities), and a  
 416 replication dataset (n=14,508  
 417 matched case/control pairs, of  
 418 which 51 patient pairs with no  
 419 dropped comorbidities), matched  
 420 by age, sex, race, and Medicaid  
 421 eligibility (a proxy for economic  
 422 status). The feature selection  
 423 method (see Appendix-2) used 45  
 424 unique comorbidities identified  
 425 from a union of the three  
 426 comorbidity indices, plus 2  
 427 condition-specific comorbidities. Of  
 428 these, 3 were removed because of  
 429 <1% prevalence. Of the remaining,  
 430 30 survived the significance and replication testing with Bonferroni correction. The visual analytical model used these surviving comorbidities (d=30), and cases consisting of CHF readmitted patients with at least one of those comorbidities (n=14,457). As shown in Fig. 3, the bipartite network analysis identified 4 biclusters, each

Model	Training	Replication/Validation	Total
<b>Visual Analytical*</b>			
COPD (cases/controls)	14,508/14,508	14,508/14,508	29,016/29,016
CHF (cases/controls)	25,775/25,775	25,775/25,775	51,550/51,550
THA/TKA (cases/controls)	8,249/8,249	8,249/8,249	16,498/16,948
<b>Classification</b>			
COPD (cases)	10,842	3,615	14,457
CHF (cases)	19,254	6,418	25,672
THA/TKA (cases)	5,257	1,753	7,010
<b>Prediction</b>			
COPD (cases/controls)	21,692/117,839	7,334/39,176	29,026/157,015
CHF (cases/controls)	38,728/183,093	12,845/61,095	51,573/244,188
THA/TKA (cases/controls)	12,376/255,203	41,44/85,049	16,520/340,252

**Table 2.** Training and replication/validation datasets used to develop the three models in each of the three index conditions.

\*The visual analytical models used 1:1 matched controls for the feature selection, and used only cases for the bipartite networks to analyze heterogeneity in readmission. The numbers shown for the visual analytical models are before removing patients with no comorbidities. The resulting cases-only datasets were used for the classification modelling as shown.



**Fig. 3.** The COPD visual analytical model showing four biclusters consisting of patient subgroups and their most frequently co-occurring comorbidities (whose labels are ranked by their univariable ORs, shown within parentheses), and their risk of readmission (shown in blue text).


Abbreviations: CardioRespShock, cardiorespiratory shock; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; Id, identifier; OB, obesity; Pneu, pneumonia; Psych, psychiatric; Uncomp, uncomplicated; HD\_other, other and unspecified heart disease; MV, history of mechanical ventilation.

433 representing a subgroup of readmitted COPD patients and their most frequently co-occurring comorbidities. The  
434 biclustering had significant modularity ( $Q=0.17$ ,  $z=7.3$ ,  $P<.001$ ), and significant replication ( $RI=0.92$ ,  $z=11.62$ ,  
435  $P<.001$ ) of comorbidity co-occurrence. Furthermore, as requested by the clinician stakeholders, we juxtaposed  
436 a ranked list of comorbidities based on their ORs for readmission in each bicluster, in addition to the risk for each  
437 of the patient subgroups.

438 The pulmonologist inspected the visualization and noted that the readmission risk of the patient subgroups had  
439 a wide range (12.7% to 19.6%) with clinical (face) validity. Furthermore, the co-occurrence of comorbidities in  
440 each patient subgroup was clinically meaningful with interpretations for each subgroup. Subgroup-1 had a low  
441 disease burden with uncomplicated hypertension leading to the lowest risk (12.7%). This subgroup represented  
442 patients with early organ dysfunction and would benefit from using checklists such as regular monitoring of  
443 blood pressure in pre-discharge protocols to reduce the risk of readmission. Subgroup-3 had mainly psychosocial  
444 comorbidities, which could lead to aspiration precipitating pneumonia leading to an increased risk for  
445 readmission (15.9%). This subgroup would benefit from early consultation with specialists (e.g., psychiatrists,  
446 therapists, neurologists, and geriatricians) that had expertise in psycho-social comorbidities, with a focus on the  
447 early identification of aspiration risks and precautions. Subgroup-2 had diabetes with complications, renal failure  
448 and heart failure and therefore had higher disease burden leading to an increased risk for readmission (17.8%)  
449 compared to Subgroup-1. This subgroup had metabolic abnormalities with greater end-organ dysfunction and  
450 would therefore benefit from case management from advanced practice providers (e.g., nurse practitioners)  
451 with rigorous adherence to established guidelines to reduce the risk of readmission. Subgroup-4 had diseases  
452 with end-organ damage including gastro-intestinal disorders, and therefore had the highest disease burden and  
453 risk for readmission (19.6%). This subgroup would also benefit from case management with rigorous adherence  
454 to established guidelines to reduce the risk of readmission. Furthermore, as patients in this subgroup typically  
455 experience complications that could impair their ability to make medical decisions, they should be provided with  
456 early consultation with a palliative care team to ensure that care interventions align with patients' preferences  
457 and values.

458 **CHF.** The inclusion and exclusion selection criteria (see Appendix-1) resulted in a training dataset ( $n=25,775$   
459 matched case/control pairs, of which 103 patient pairs with no dropped comorbidities) and a replication dataset  
460 ( $n=25,775$  matched case/control pairs, of which 104 patient pairs with no dropped comorbidities), matched by  
461 age, sex, race, and Medicaid eligibility (a proxy for economic status). The feature selection method (see  
462 Appendix-2) used 42 unique comorbidities identified from a union of the three comorbidity indices, plus 1  
463 condition-specific comorbidity. Of these, 1 comorbidity was removed because of  $<1\%$  prevalence. Of those  
464 remaining, 37 survived the significance and replication testing with Bonferroni correction. The visual analytical  
465 model (Fig. 4) used these surviving comorbidities ( $d=37$ ), and cases consisting of CHF readmitted patients with  
466 at least one of those comorbidities ( $n=25,672$ ). As shown in Fig. 4, the bipartite network analysis of the CHF cases  
467 identified 4 biclusters, each representing a subgroup of readmitted CHF patients and their most frequently co-  
468 occurring comorbidities. The analysis revealed that the biclustering had significant modularity ( $Q=0.17$ ,  $z=8.69$ ,  
469  $P<.001$ ), and significant replication ( $RI=0.94$ ,  $z=17.66$ ,  $P<.001$ ) of comorbidity co-occurrence. Furthermore, as  
470 requested by the clinicians, we juxtaposed a ranked list of comorbidities based on their ORs for readmission in  
471 each bicluster, in addition to the risk for each of the patient subgroups.

472 The geriatrician inspected the visualization and noted that the readmission risk of the patient subgroups, ranging  
473 from 15.1% to 19.9%, was wide with clinical (face) validity. Furthermore, the co-occurrence of comorbidities in  
474 each patient subgroup was clinically meaningful. Subgroup-1 had chronic but stable conditions, and therefore  
475 had the lowest risk for readmission (15.1%). Subgroup-3 had mainly psychosocial comorbidities, but were not as  
476 clinically unstable or fragile compared to subgroups 2 and 4, and therefore had medium risk (16.6%). Subgroup-  
477 2 had severe chronic conditions, making them clinically fragile (with potential benefits from early palliative and  
478 hospice care referrals), and were therefore at high risk for readmission if non-palliative approaches were used  
479 (19.9%). Subgroup-4 had severe acute conditions which were also clinically unstable, associated with substantial  
480 disability and care debility, and therefore at high risk for readmission and recurrent intensive care unit (ICU) use  
481 (19.9%).




**Fig. 4.** The CHF visual analytical model showing four biclusters consisting of patient subgroups and their most frequently co-occurring comorbidities (whose labels are ranked by their univariable ORs, shown within parentheses), and their risk of readmission (shown in blue text).

Abbreviations: CABG, coronary artery bypass graft; CardioRespShock, cardiorespiratory shock; CHF, congestive heart failure; comp, complicated; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; Id, identifier; Neuro, neurologic; OB, obesity; Pneu, pneumonia; Psych, psychiatric; Uncomp, uncomplicated; uri, urinary; w\_comp, with complications; HD\_other, other and unspecified heart disease.

482 **THA/TKA.** The inclusion and exclusion selection criteria (see Appendix-1) resulted in a training dataset (n=8,249  
 483 matched case/control pairs, of which 1239 patient pairs with no dropped comorbidities) and a replication  
 484 dataset (n=8,249 matched case/control pairs, of which 1264 patient pairs with no dropped comorbidities),  
 485 matched by age, sex, race, and Medicaid eligibility (a proxy for economic status). The feature selection (see  
 486 Appendix-2) used 39 unique comorbidities identified from the three comorbidity indices plus 2 condition-specific  
 487 comorbidities. Of these, 11 comorbidities were removed because of <1% prevalence. Of the remaining, 11  
 488 survived the significance and replication testing with Bonferroni correction. The visual analytical model (Fig. 5)  
 489 used these surviving comorbidities (d=11), and cases consisting of readmitted patients with at least one of those  
 490 comorbidities (n=7,010).

491 As shown in Fig. 5, the bipartite network analysis of the THA/TKA cases identified 7 biclusters, each representing  
 492 a subgroup of readmitted THA/TKA patients and their most frequently co-occurring comorbidities. The analysis  
 493 revealed that the biclustering had significant modularity ( $Q=0.31$ ,  $z=2.52$ ,  $P=.011$ ), and significant replication  
 494 ( $RI=0.89$ ,  $z=3.15$ ,  $P=.002$ ) of comorbidity co-occurrence. Furthermore, as requested by the clinician stakeholders,  
 495 we juxtaposed a ranked list of comorbidities based on their ORs for readmission in each bicluster, in addition to  
 496 the risk for each of the patient subgroups.

497 The geriatrician inspected the network and noted that TKA patients, in general, were healthier compared to THA  
 498 patients, and therefore the network was difficult to interpret when the two index conditions were merged  
 499 together. While our analysis was constrained because we were using the conditions as defined by CMS, these  
 500 results nonetheless suggest that the interpretations did not suffer from a confirmation bias (manufactured  
 501 interpretations to fit the results). However, he noted that the range of readmission risk had clinical (face) validity.



**Fig. 5.** The THA/TKA visual analytical model showing four biclusters consisting of patient subgroups and their most frequently co-occurring comorbidities (whose labels are ranked by their univariable ORs, shown within parentheses), and their risk for readmission (shown in blue text).

Abbreviations: CHF, congestive heart failure; comp, complicated; COPD, chronic obstructive pulmonary disease; Id, identifier; OB, obesity; Symp, symptom; THA/TKA, total hip/knee arthroplasty; Uncomp, uncomplicated.

502 Furthermore, subgroups 2, 4, and 5 had more severe comorbidities related to lung, heart, and kidney, and  
503 therefore had a higher risk for readmission compared to subgroups 1, 6, and 7 that had less severe comorbidities  
504 with a lower risk for readmission. In addition, subgroups 2, 5, 6 and 7 would benefit from chronic care case  
505 management from advanced practice providers (e.g., nurse practitioners). Finally, subgroups 2 and 5 could  
506 benefit from using well-established guidelines for CHF and COPD, subgroup 7 would benefit from mental health  
507 care and management of psycho-social comorbidities, and subgroup 6 would benefit from care for obesity and  
508 metabolic disease management.

### 509 Classification Modeling

510 The classification model used multinomial logistic regression in each index condition (see Appendix-3 for the  
511 model coefficients) to predict the membership of patients using subgroups (identified from the above visual  
512 analytical models). The results revealed that in each index condition, the classification model had high accuracy  
513 in classifying all the cases in the full dataset (training dataset used in the visual analytical modeling). Similarly,  
514 the internal validation results using a 75%-25% split of the above dataset also had high classification accuracy  
515 (Table 3 with classification accuracy divided into quantiles). We report both results for each index condition:

516 **COPD.** The model correctly predicted subgroup membership for 99.90% of the cases (14443/14457) in the full  
517 dataset. Furthermore, as shown in Table 3, the internal validation results revealed that the percentage of COPD  
518 cases correctly assigned to a subgroup in the testing dataset, ranged from 99.10% to 100.00%, with a median  
519 (Q.50) of 99.60%, and with 95% being in the range from 99.30% to 99.80%.

520 **CHF.** The model correctly predicted subgroup membership for 99.20% of the cases (25476/25672) in the full  
521 dataset. Furthermore, as shown in Table 3, the internal validation results revealed that the percentage of CHF

Models	Quantiles					Summary			
	Q .025	Q .25	Q .50	Q .75	Q .975	Min	Max	Mean	SD
<b>COPD</b>									
Training (n=10842)	99.90	100.00	100.00	100.00	100.00	99.70	100.00	100.00	0.02
Testing (n=3615)	99.30	99.40	99.60	99.60	99.80	99.10	100.00	99.60	0.15
<b>CHF</b>									
Training (n=19254)	99.40	99.50	99.60	99.60	99.80	99.00	99.90	99.57	0.11
Testing (n=6418)	99.00	99.30	99.30	99.40	99.60	98.70	99.70	99.34	0.15
<b>THA/TKA</b>									
Training (n=5257)	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	0.00
Testing (n=1753)	99.70	99.80	99.90	99.90	100.00	99.40	100.00	99.86	0.09

**Table 3.** Internal validation results showing the percentage of COPD, CHF, and THA/TKA patients correctly-assigned to a subgroup by the classification models in each condition.

522 cases correctly assigned to a subgroup in the testing dataset, ranged from 98.70% to 99.70%, with a median  
523 (Q.50) of 99.30%, and with 95% being in the range from 99.00% to 99.60%.

524 **THA/TKA.** The model correctly predicted subgroup membership 100.00% of the cases (7010/7010) in the full  
525 dataset. Furthermore, as shown in Table 3, the internal validation results revealed that the percentage of CHF  
526 cases correctly assigned to a subgroup in the testing dataset, ranged from 99.40% to 100.00%, with a median  
527 (Q.50) of 99.90%, and with 95% being in the range from 99.70% to 100.00%.


528 **Application of the Classification Model to Generate Information for Other Models.** The above classification  
529 model was used to classify 100% cases and 100% controls for use in the prediction model (described below).  
530 Furthermore, the proportion of cases and controls classified into each subgroup was used to calculate the risk  
531 of readmission for each subgroup (see Appendix 3). As this subgroup risk information was requested by the  
532 clinicians to improve interpretability of the visual analytical model, the values were juxtaposed next to the  
533 respective subgroups in the bipartite network visualizations (see blue text in Fig. 3-5).

### 534 Prediction Modeling

535 For each of the three index conditions, we developed two binary logistic regression models to predict  
536 readmission, with comorbidities in addition to sex, age, and race: (1) **Standard Model** representing all patients  
537 without subgroup membership, similar to the CMS  
538 models; and (2) **Hierarchical Model** with an  
539 additional variable that adjusted for subgroup  
540 membership.

541 **COPD.** The inclusion and exclusion selection criteria  
542 (see Appendix-1) resulted in a cohort of 186,041  
543 patients (29,026 cases and 157,015 controls). As  
544 shown in Fig. 6A, the Standard Model had a C-  
545 statistic of 0.624 (95% CI: 0.617-0.631) which was not  
546 significantly ( $P=.8578$ ) different from the  
547 Hierarchical Model that had a C-statistic of 0.625  
548 (95% CI: 0.618-0.632). The calibration plots revealed  
549 that both models had a slope close to 1, and an  
550 intercept close to 0 (see Appendix-4).

551 As shown in Fig. 6B, the Standard Model was used to  
552 measure the predictive accuracy of patients in each  
553 subgroup separately. The results showed that  
554 Subgroup-1 had a lower C-statistic compared to  
555 Subgroup-3 and Subgroup-4. While the C-statistics in  
556 Fig. 6A and Fig. 6B cannot be compared as they are



**Fig. 6. (A)** Predictive accuracy of the Standard Model compared to the Hierarchical model in COPD, as measured by the C-Statistic. The C-statistic for the CMS published model is shown as a dotted line. **(B)** Predictive accuracy of the Standard Model when applied separately to patients classified to each subgroup. S-1 has lower accuracy compared to S-3 and S-4. (C-statistics in A and B cannot be compared as they are based on models from different populations).

557 based on models developed from different  
558 populations, these results reveal that the current  
559 CMS readmission model for CHF might be  
560 underperforming for one COPD patient subgroup,  
561 pinpointing which one might benefit by a Subgroup-  
562 Specific Model.


563 **CHF.** The inclusion and exclusion selection criteria  
564 (see Appendix-1) resulted in a cohort of 295,761  
565 patients (51,573 cases and 244,188 controls). As  
566 shown in Fig. 7A, the Standard Model had a C-  
567 statistic of 0.600 (95% CI: 0.595-0.605), which was  
568 not significantly different ( $P=0.2864$ ) from the  
569 Hierarchical Model that also had a C-statistic of  
570 0.600 (95%CI: 0.595-0.605). The calibration plots  
571 revealed that all models had a slope close to 1, and  
572 an intercept close to 0 (see Appendix-4).

573 As shown in Fig. 7B, the Standard Model was used to  
574 measure the predictive accuracy of patients in each  
575 subgroup separately. The results showed that  
576 Subgroup-1 had a lower C-statistic compared to  
577 Subgroup-4. While the C-statistics in Fig. 7A and Fig.  
578 7B cannot be compared as they are based on models  
579 developed from different populations, but similar to the  
580 results in COPD, these results reveal that the current  
CMS readmission model for CHF might be underperforming  
for one CHF patient subgroup, pinpointing which one  
might benefit by a Subgroup-Specific Model.


581 **THA/TKA.** The application of the inclusion and exclusion selection criteria (see Appendix-1) resulted in a cohort  
582 of 356,772 patients (16,520 cases and 340,252 controls). As shown in Fig. 8A, the Standard Model had a C-  
583 statistic of 0.638 (95% CI: 0.629-0.646), which was not significantly different ( $P=0.6817$ ) from the Hierarchical  
584 Model that had a C-statistic of 0.638 (95% CI: 0.629-0.647). The calibration plots (see Appendix-4) revealed that  
585 both models had a slope close to 1, and an intercept  
586 close to 0 (see Appendix-4).

587 As shown in Fig. 8B, the Standard Model was used to  
588 measure the predictive accuracy of patients in each  
589 subgroup separately. The results showed that  
590 Subgroup-1 had a lower C-statistic compared to  
591 Subgroup-4. Again, while the C-statistics in Fig. 8A  
592 and Fig. 8B cannot be compared as they are based  
593 on models developed from different populations,  
594 similar to the results in COPD, these results reveal  
595 that the current CMS readmission model for  
596 THA/TKA might be underperforming for 4 patient  
597 subgroups, pinpointing which ones might benefit by  
598 Subgroup-Specific Models.

599 **CMS Standard Model vs. CMS Hierarchical Model.**  
600 Unlike the CMS published models, the above models  
601 used only the comorbidities that survived feature  
602 selection. Therefore, to perform a head-to-head  
603 comparison with the published CMS models, we also  
604 developed a CMS Standard Model (using the same  
605 variables from the published CMS model), and



**Fig. 7. (A)** Predictive accuracy of the Standard Model compared to the Hierarchical model in CHF as measured by the C-Statistic. The C-statistic for the CMS published model is shown as a dotted line. **(B)** Predictive accuracy of the Standard Model when applied separately to patients classified to each subgroup. S-1 has lower accuracy compared to S-3 and S-4. (C-statistics in A and B cannot be compared as they are based on models from different populations).



**Fig. 8. (A)** Predictive accuracy of the Standard Model compared to the Hierarchical model in THA/TKA as measured by the C-Statistic. The C-statistic for the CMS published model is shown as a dotted line. **(B)** Predictive accuracy of the Standard Model when applied separately to patients classified to each subgroup. S-1 has lower accuracy compared to S-7. (C-statistics in A and B cannot be compared as they are based on models developed from different populations).



Model	NRI		IDI
	Categorical (95% Interval)	Continuous (95% Interval)	IDI (95% Interval)
COPD	.023 (.012, .034)*	.059 (.034, .083)*	.0002 (-.0004, .0008)
CHF	-.010 (-.016, -.0004)*	-.038 (-.057, -.019)*	-.0006(-.0009,-.0003)*
THA/TKA	.022 (.012, .032)*	.111 (.080, .142)*	-.003(-.002,-.003)*

**Table 4.** Comparison of the CMS Standard Model with the CMS Hierarchical Model across the three index conditions based on NRI and IDI (\* = significant at the .05 level).

606 compared it to the corresponding CMS Hierarchical Model (with an additional variable for subgroup  
607 membership) in each condition. Similar to the models in Fig. 6-8, there were no significant differences in the C-  
608 statistics between the two modeling approaches in any condition (see Appendix-4). However, as shown in Table  
609 4, the CMS Hierarchical Model for COPD had significantly higher NRI, but not significantly higher NDI compared  
610 to the CMS Standard Model; the CMS Hierarchical Model for CHF had a significantly lower NRI and IDI compared  
611 to the CMS Standard Model, and the CMS Hierarchical Model for THA/TKA had a significantly higher NDI and IDI  
612 compared to the CMS Standard Model. Furthermore, similar to the results in 6B-8B, when the CMS Standard  
613 Model was used to predict readmission separately in subgroups within each index condition, it identified  
614 subgroups that underperformed, pinpointing which ones might benefit by a Subgroup-Specific Model (See  
615 Appendix-4). In summary, the comparisons between the CMS Standard Models and the respective CMS  
616 Hierarchical Models showed that in two conditions (COPD and THA/TKA), there was a small but statistically  
617 significant improvement in discriminating between the readmitted and not readmitted patients as measured by  
618 NRI, but not as measured by the C-statistic or IDI, and that a subgroup in each index condition might be  
619 underperforming when using the CMS Standard Model.

## 620 DISCUSSION

### 621 Overview

622 Our overall approach of using the MIPS framework for identifying patient subgroups through visual analytics,  
623 and using those subgroups to build classification and prediction models, revealed strengths and limitations for  
624 each modeling approach, and for our data source. This examination led to insights for developing future clinical  
625 decision support systems, and a methodological framework for improving the clinical interpretability of  
626 subgroup modeling results.

### 627 Strengths and Limitations of Modeling Methods and Data Source

628 Visual Analytical Modeling. The results revealed three strengths of the visual analytical modeling: (1) the use of  
629 bipartite networks to simultaneously model patients and comorbidities, enabled the automatic identification of  
630 patient-comorbidity biclusters, and the integrated analysis of co-occurrence and risk; (2) the use of a bipartite  
631 modularity maximization algorithm to identify the biclusters enabled the measurement of the strength of the  
632 biclustering, critical for gauging its significance; and (3) the use of a graph representation enabled the results to  
633 be visualized through a network. Furthermore, the request from the domain experts to juxtapose the risk of  
634 each subgroup with their visualizations appeared to be driven by a need to reduce working memory loads (from  
635 having to remember that information spread over different outputs), which could have enhanced their ability to  
636 match bicluster patterns with chunks (previously-learned patterns of information) stored in long-term memory.  
637 The resulting visualizations enabled them to recognize subtypes based on co-occurring comorbidities in each  
638 subgroup, reason about the processes that precipitate readmission based on the risk of each subtype relative to  
639 the other subtypes, and propose interventions that were targeted to those subtypes and their risks. Finally, the  
640 fact that the geriatrician could not fully interpret the THA/TKA network because it mixed two fairly different  
641 conditions, suggests that the clinical interpretations were not the result of a *confirmation bias* (interpretations  
642 leaning towards fitting the results).

643 However, the results also revealed two limitations: (1) while modularity is estimated using a closed-form  
644 equation (formula), no closed-form equation exists to estimate the modularity variance, which is necessary to  
645 measure its significance. To estimate modularity variance, we therefore used a permutation test by generating

646 1000 random permutations of the data, and then compared the modularity generated from the real data to the  
647 mean modularity generated from the permuted data. Given the size of our datasets (ranging from 7K-25K  
648 patients), this computationally-expensive test took approximately 7 days to complete, despite the use of a  
649 dedicated server with multiple cores; and (2) while bicluster modularity was successful in identifying significant  
650 and meaningful patient-comorbidity biclusters, the visualizations themselves were extremely dense, and  
651 therefore potentially concealed patterns within and between the subgroups. Future research should explore a  
652 closed-form equation to estimate modularity variance, with the goal of accelerating the estimation of modularity  
653 significance, and more powerful analytical and visualization methods to reveal intra- and inter-cluster  
654 associations in large and dense networks.

655 Classification Modeling. The results revealed two strengths of the classification modeling: (1) the use of a simple  
656 multinomial classifier was adequate to predict with high accuracy to which subgroup a patient belonged; (2)  
657 because the model produced membership probabilities for each patient for each subgroup, the model captured  
658 the dense inter-cluster edges observed in the network visualization; and (3) the coefficients of the trained  
659 classifier could be inspected by an analyst making it more transparent (relative to most deep-learning classifiers  
660 which tend to be a black box).

661 However, because we dichotomized the classification probabilities into a single subgroup membership, our  
662 approach did not fully leverage the membership probabilities for modeling and visual interpretation. For  
663 example, some patients have high classification probabilities (representing strong membership) to a single  
664 subgroup (as shown by patients in the outer periphery of the biclusters with edges only within their bicluster),  
665 whereas others have equal probabilities to all subgroups (as shown in the inner periphery of the biclusters with  
666 edges going to multiple clusters). Future research should explore incorporating the probability of subgroup  
667 membership into the design of hierarchical models to improve predictive accuracy, and visualization methods  
668 to help clinicians interpret patients with different profiles of membership strength, with the goal of designing  
669 patient-specific interventions.

670 Predictive Modeling. The results revealed two strengths of the predictive modeling: (1) the use of the Standard  
671 Model to measure predictive accuracy across the subgroups helped to pinpoint which subgroups tend to have  
672 lower predictive accuracy compared to the rest, and therefore which of them could benefit from a more complex  
673 but accurate subgroup-specific model; and (2) despite the use of a simple Hierarchical Model with a  
674 dichotomized membership label for each patient, the predictive CMS models detected significant differences in  
675 the prediction accuracy as measured by NRI in two of the conditions, when compared to the CMS Standard  
676 Models. However, the results also revealed that the differences in predictive accuracy as measured by the C-  
677 statistic and NDI were small, suggesting that comorbidities on their own were potentially insufficient for  
678 accurately predicting readmission. Future research should explore the use of electronic health records, and  
679 multiple subgroup-specific models targeted to each subgroup, to improve the predictive accuracy of the models.

680 Data Source. The Medicare claims data had four key strengths: (1) scale of the datasets which enabled subgroup  
681 identification with sufficient statistical power; (2) spread of the data collected from across the US which enabled  
682 generalizability of the results; (3) data about older adults which enabled examination of subgroups in an  
683 underrepresented segment of the US population; and (4) data used by CMS to build predictive readmission  
684 models, which enabled a head-to-head comparison with the hierarchical modeling approach.

685 However, the data had two critical limitations. (1) As we compared our models with the CMS models, we had to  
686 use the same definition for controls (90 days with no readmission) that had been used, which introduced a  
687 selection bias that exaggerates the separation between cases and controls. Similarly, by excluding patients who  
688 died, this exclusion criterion potentially biased the results towards healthier patients. (2) Administrative data  
689 have known limitations such as the lack of comorbidity severity and test results, which could strongly impact the  
690 accuracy of predictive models. Future research should consider the use of national-level electronic health record  
691 (EHR) data such as those being assembled by the National COVID Cohort Collaborative (N3C) [59], and the  
692 TriNetX [60] initiatives, which could overcome the above limitations by providing laboratory values and  
693 comorbidity severity, but could also introduce new as yet unknown limitations.

## 694 **Implications for Clinical Decision-Support Systems that Leverage Patient Subgroups**

695 While the focus of this project was to develop and evaluate the MIPS framework, its application to three index  
696 conditions coupled with extensive discussions with clinicians led to insights for designing a future clinical decision  
697 support system. Such a system could integrate outputs from all three models. As we have shown, the visual  
698 analytical model automatically identified and visualized the patient subgroups, which enabled the clinicians to  
699 comprehend the co-occurrence and risk information in the visualization, reason about the processes that lead  
700 to readmission in each subgroup, and design targeted interventions. The classification model leveraged the  
701 observation that many patients have comorbidities in other biclusters (shown by a large number of edges  
702 between biclusters), and accordingly generated a membership probability of a patient belonging to each  
703 bicluster, from which the highest was chosen for bicluster membership. Finally, the predictive model predicts  
704 the risk for readmission for a patient, by using in the future the most accurate model designed for the bicluster  
705 to which the patient belongs.

706 The outputs from the above models could be integrated into a clinical decision support system to provide  
707 recommendations for a specific patient using the following algorithm: (1) use the classifier to generate the  
708 membership probability (MP) of a new patient belonging to each subgroup; (2) multiply the MP in each subgroup  
709 with the patient's risk (R) for readmission provided by the predictive model for that subgroup, to generate an  
710 importance score [ $IS = f(MP) \times g(R)$ ] for the respective intervention; (3) rank the subgroups and their respective  
711 interventions using IS; and (4) use the ranking to display in descending order, the subgroup comorbidity profiles  
712 along with their respective potential mechanisms, recommended treatments, and the respective IS. Such model-  
713 based information, displayed through a user-friendly interface, could enable a clinician to rapidly scan the ranked  
714 list to (a) determine why a specific patient's profile fits into one or more subgroups, (b) review the potential  
715 mechanisms and interventions ranked by their importance, and (c) use the combined information to design a  
716 treatment that is customized for the real-world context of the patient. Consequently, such a clinical decision  
717 support system could not only provide a quantitative ranking of membership to different subgroups, and the  
718 importance score for the associated interventions, but also enable the clinician to understand the rationale  
719 underlying those recommendations, making the system interpretable and explainable. Comparative evaluation  
720 of such a system to standard care could determine its clinical efficacy.

## 721 **Implications for Analytical Granularity to Enhance the Interpretability of Patient Subgroups**

722 While the visual analytical model enabled the clinicians to interpret the patient subgroups, they were unable to  
723 interpret the associations within and between the subgroups due to the large number of nodes in each bicluster  
724 and the dense edges between them. Several network filtering methods [61, 62] have been developed to "thin  
725 out" such dense networks such as by dropping or bundling nodes and edges based on user-defined criteria, to  
726 improve visual interpretation. However, such filtering could bias the results, or modify the clusters resulting  
727 from the reduced data.

728 An alternate approach that preserves the full dataset leverages the notion of analytical granularity, where the  
729 data is progressively analyzed at different levels. For example, we have analyzed COVID-19 patients [11] at the  
730 cohort, subgroup, and patient levels, and we are currently using the same approach to examine symptom co-  
731 occurrence and risk at each level in Long COVID patients. Our preliminary results suggest that analyzing data at  
732 different levels of granularity enables clinicians to progressively interpret patterns such as within and between  
733 subgroups, in addition to guiding the systematic development of new algorithms. For example, at the subgroup  
734 level, we have designed an algorithm that identifies which patient subgroups have a significantly higher  
735 probability for having characteristics that are clustered in another subgroup, providing critical information to  
736 clinicians about how to design interventions for such overlapping subgroups; at the patient level, we have  
737 identified patients that are outliers to their subgroups based on their pattern of characteristics inside and outside  
738 their subgroup. Such patient outliers could be flagged to examine if they need individualized interventions versus  
739 those recommended for the rest of their subgroup. Such analytical granularity could therefore inform the design  
740 of interventions by clinicians, in addition to the design of decision support systems that provide targeted and  
741 interpretable recommendations to physicians, who can then customize them to fit the real-world context of a  
742 patient.

## 743 Implications of the MIPS Framework for Precision Medicine

744 While we have demonstrated the application of the MIPS framework across multiple readmission conditions, its  
745 architecture has three properties that should enable its generalizability across other medical conditions. First,  
746 as shown in Fig. 2, the framework is *modular* with explicit inputs and outputs, enabling the use of other methods  
747 at each of the three modeling steps. For example, the framework could use other biclustering (e.g., Non-  
748 negative Matrix Factorization [63]), classification (e.g., deep learning [64]), and prediction methods (e.g.,  
749 subgroup-specific modeling [17]). Second, the framework is *extensible*, enabling an elaboration of the methods  
750 at each modeling step to improve the analysis and interpretation of subgroups. For example, as discussed above,  
751 the analytical granularity at the cohort, subgroup, and patient levels could improve the interpretability of  
752 subgroups in large and dense datasets. Third, the framework is *integrative* as it systematically combines the  
753 strengths of machine learning, statistical, and precision medicine approaches. For example, the visual analytical  
754 modeling leverages search algorithms to discover co-occurrence in large datasets; the classification and  
755 prediction modeling leverages probability theory to measure the risk of co-occurrence patterns; and clinicians  
756 leverage medical knowledge and human cognition to interpret patterns of co-occurrence and risk for designing  
757 precision-medicine interventions. Such integration of different models and their interpretation operationalizes  
758 *team-centered informatics* [65] designed to facilitate data scientists, biostatisticians, and clinicians in  
759 multidisciplinary translational teams [66] to work more effectively across disciplinary boundaries, with the goal  
760 of designing interventions for precision medicine. Our current research tests the generality of the MIPS  
761 framework in other conditions such as Long COVID and Post-Stroke Depression, with the goal of designing and  
762 evaluating precision medicine interventions targeted to patient subgroups.

## 763 CONCLUSIONS

764 Although a primary goal of precision medicine is to identify patient subgroups and to design targeted  
765 interventions, few methods automatically identify both patient subgroups and their co-occurring characteristics  
766 simultaneously, measure their significance, and visualize the results. Here we demonstrated the use of the MIPS  
767 framework, which used a three-step approach to model and interpret patient subgroups. A visual analytical  
768 method automatically identified statistically significant and replicated patient subgroups and their frequently  
769 co-occurring comorbidities. Next, a multinomial logistic regression classifier had high accuracy in correctly  
770 classifying patients into the patient subgroups identified by the visual analytical model. Finally, despite using a  
771 simple hierarchical logistic regression model to incorporate subgroup information, the predictive models had a  
772 statistically significant improvement in discriminating between the readmitted and not readmitted patients in  
773 two of the three readmission conditions, and further analysis pinpointed for which patient subgroups the current  
774 CMS model might be underperforming. Finally, by integrating the co-occurrence and risk patterns in a  
775 visualization, the MIPS framework enabled clinicians to interpret the patient subgroups, reason about  
776 mechanisms precipitating hospital readmission, and design targeted interventions.

777 However, evaluation of the methods across three readmission index conditions also helped to identify  
778 limitations of the models and the data. The visual analytical model was too dense to enable the clinicians to  
779 interpret the associations within and between the subgroups, and the absence of a closed-form equation to  
780 measure modularity variance required a computationally-expensive process to measure the significance of the  
781 biclustering. Furthermore, the small improvement in predictive accuracy suggested that comorbidities on their  
782 own were insufficient for predicting hospital readmission.

783 By leveraging the modular and extensible nature of the MIPS framework, future research should address the  
784 above limitations by developing more powerful algorithms which analyze subgroups at different levels of  
785 granularity to improve the interpretability of intra- and inter-cluster associations, and the evaluation of  
786 subgroup-specific models to predict outcomes. Furthermore, EHR data made available through national-level  
787 data initiatives such as N3C and TriNetX now provide access to critical variables including laboratory results and  
788 comorbidity severity, which should lead to higher predictive power for predicting adverse outcomes. Finally,  
789 extensive discussions with clinicians provided implications for the design of future decision support systems,  
790 which could integrate outputs from the three models to provide for a specific patient, predicted subgroup  
791 memberships, ranked interventions, along with associated subgroup profiles and mechanisms. Such

792 interpretable and explainable systems could enable clinicians to use patient subgroup information for informing  
793 the design of precision medicine interventions, with the goal of reducing adverse outcomes such as unplanned  
794 hospital readmissions and beyond.

## 795 **ACKNOWLEDGEMENTS**

796 We thank Tianlong Chen, Clark Andersen, Yu-Li Lin, and Emmanuel Santillana for performing the analyses on this  
797 project. This study was supported in part by the Patient-Centered Outcomes Research Institute (ME-1511-  
798 33194), the Clinical and Translational Science Award (UL1 TR001439) from the National Center for Advancing  
799 Translational Sciences at the National Institutes of Health, and by the National Library of Medicine (R01  
800 LM012095) at the National Institutes of Health. The content is solely the responsibility of the authors, and does  
801 not necessarily represent the official views of the Patient-Centered Outcomes Research Institute, or the National  
802 Institutes of Health. The Medicare data were analyzed using a CMS data-use agreement (CMS DUA RSCH-2017-  
803 51404).

## 804 REFERENCES

- 805 1. McClellan J, King M-C. Genetic Heterogeneity in Human Disease. *Cell*. 141(2):210-7. doi:  
806 10.1016/j.cell.2010.03.032.
- 807 2. Waldman SA, Terzic A. Therapeutic targeting: a crucible for individualized medicine. *Clinical Pharmacology*  
808 & *Therapeutics*. 2008;83(5):651-4.
- 809 3. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular  
810 subtypes respond differently to preoperative chemotherapy. *Clinical cancer research: an official journal of*  
811 *the American Association for Cancer Research*. 2005;11(16):5678-85. Epub 2005/08/24. doi: 10.1158/1078-  
812 0432.ccr-04-2421. PubMed PMID: 16115903.
- 813 4. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast  
814 carcinomas distinguish tumor subclasses with clinical implications. *Proceedings of the National Academy of*  
815 *Sciences of the United States of America*. 2001;98(19):10869-74. Epub 2001/09/13. doi:  
816 10.1073/pnas.191367098. PubMed PMID: 11553815; PubMed Central PMCID: PMCPMC58566.
- 817 5. Fitzpatrick AM, Teague WG, Meyers DA, Peters SP, Li X, Li H, et al. Heterogeneity of severe asthma in  
818 childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart,  
819 Lung, and Blood Institute Severe Asthma Research Program. *The Journal of allergy and clinical immunology*.  
820 2011;127(2):382-9.e1-13. Epub 2011/01/05. doi: 10.1016/j.jaci.2010.11.015. PubMed PMID: 21195471;  
821 PubMed Central PMCID: PMCPMC3060668.
- 822 6. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al. Cluster analysis and clinical asthma  
823 phenotypes. *American journal of respiratory and critical care medicine*. 2008;178(3):218-24. Epub  
824 2008/05/16. doi: 10.1164/rccm.200711-1754OC. PubMed PMID: 18480428; PubMed Central PMCID:  
825 PMCPMC3992366.
- 826 7. Lotvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, et al. Asthma endotypes: a new approach  
827 to classification of disease entities within the asthma syndrome. *The Journal of allergy and clinical*  
828 *immunology*. 2011;127(2):355-60. Epub 2011/02/02. doi: 10.1016/j.jaci.2010.11.037. PubMed PMID:  
829 21281866.
- 830 8. Nair P, Pizzichini MMM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al. Mepolizumab for  
831 Prednisone-Dependent Asthma with Sputum Eosinophilia. *New England Journal of Medicine*.  
832 2009;360(10):985-93. doi: doi:10.1056/NEJMoa0805435. PubMed PMID: 19264687.
- 833 9. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab Treatment in  
834 Patients with Severe Eosinophilic Asthma. *New England Journal of Medicine*. 2014;371(13):1198-207. doi:  
835 10.1056/NEJMoa1403290.
- 836 10. Collins FS, Varmus H. A new initiative on precision medicine. *The New England journal of medicine*.  
837 2015;372(9):793-5. Epub 2015/01/31. doi: 10.1056/NEJMp1500523. PubMed PMID: 25635347.
- 838 11. Bhavnani SK, Kummerfeld E, Zhang W, Kuo Y-F, Garg N, Visweswaran S, et al. Heterogeneity in COVID-19  
839 Patients at Multiple Levels of Granularity: From Biclusters to Clinical Interventions. *Proceedings of the*  
840 *American Medical Informatics Association Summits*. 2021:112-21. doi: PMID: 34457125.
- 841 12. Bhavnani SK, Dang B, Penton R, Visweswaran S, Bassler KE, Chen T, et al. How High-Risk Comorbidities Co-  
842 Occur in Readmitted Patients With Hip Fracture: Big Data Visual Analytical Approach. *JMIR Med Inform*.  
843 2020;8(10):e13567. doi: 10.2196/13567.
- 844 13. Lacy ME, Wellenius GA, Carnethon MR, Loucks EB, Carson AP, Luo X, et al. Racial Differences in the  
845 Performance of Existing Risk Prediction Models for Incident Type 2 Diabetes: The CARDIA Study. *Diabetes*  
846 *care*. 2015. Epub 2015/12/03. doi: 10.2337/dc15-0509. PubMed PMID: 26628420.
- 847 14. Baker JJ. Medicare payment system for hospital inpatients: diagnosis-related groups. *Journal of health care*  
848 *finance*. 2002;28(3):1-13. Epub 2002/06/25. PubMed PMID: 12079147.
- 849 15. Lipkovich I, Dmitrienko A, Denne J, Enas G. Subgroup identification based on differential effect search--a  
850 recursive partitioning method for establishing response to treatment in patient subpopulations. *Statistics in*  
851 *medicine*. 2011;30(21):2601-21. Epub 2011/07/26. doi: 10.1002/sim.4289. PubMed PMID: 21786278.
- 852 16. Kehl V, Ulm K. Responder identification in clinical trials with censored data. *Comput Stat Data Anal*.  
853 2006;50(5):1338-55. doi: 10.1016/j.csda.2004.11.015.

- 854 17. Hastie T, Tibshirani R, Friedman J. *The Elements of Statistical Learning*. New York, NY, USA: Springer New  
855 York Inc.; 2001.
- 856 18. Abu-jamous B, Fa R, Nandi AK. *Integrative Cluster Analysis in Bioinformatics*. Chichester, West Sussex, United  
857 Kingdom: John Wiley & Sons, Ltd.; 2015.
- 858 19. Lochner KA, Cox CS. Prevalence of multiple chronic conditions among Medicare beneficiaries, United States,  
859 2010. *Preventing chronic disease*. 2013;10:E61. Epub 2013/04/27. doi: 10.5888/pcd10.120137. PubMed  
860 PMID: 23618541; PubMed Central PMCID: PMCPCmc3652723.
- 861 20. Newman MEJ. *Networks: An Introduction*. Oxford, United Kingdom: Oxford University Press; 2010.
- 862 21. Shabalin AA, Weigman VJ, Perou CM, Nobel AB. Finding large average submatrices in high dimensional data.  
863 2009;985-1012. doi: 10.1214/09-AOAS239.
- 864 22. Odibat O, Reddy CK. Efficient Mining of Discriminative Co-clusters from Gene Expression Data. *Knowledge  
865 and information systems*. 2014;41(3):667-96. Epub 2015/02/03. doi: 10.1007/s10115-013-0684-0. PubMed  
866 PMID: 25642010; PubMed Central PMCID: PMCPCmc4308820.
- 867 23. Folino F, Pizzuti C, Ventura M. A comorbidity network approach to predict disease risk. *Proceedings of the  
868 First international conference on Information technology in bio- and medical informatics; Bilbao, Spain*.  
869 1885260: Springer-Verlag; 2010. p. 102-9.
- 870 24. Newman MEJ. Modularity and community structure in networks. *Proceedings of the National Academy of  
871 Sciences*. 2006;103(23):8577-82. doi: 10.1073/pnas.0601602103.
- 872 25. Newman MEJ. Fast algorithm for detecting community structure in networks. *Physical Review E*.  
873 2004;69(6):066133.
- 874 26. Trevino III S, Nyberg A, Del Genio CI, Bassler KE. Fast and accurate determination of modularity and its effect  
875 size. *J Stat Mech*. 2015;P02003.
- 876 27. Chauhan R, Ravi J, Datta P, Chen T, Schnappinger D, Bassler KE, et al. Reconstruction and topological features  
877 of the sigma factor regulatory network of *Mycobacterium tuberculosis*. In Review.
- 878 28. Dang B, Chen T, Bassler KE, Bhavnani SK. *ExplodeLayout: Enhancing the Comprehension of Large and Dense  
879 Networks*. *AMIA Jt Summits Transl Sci Proc* 2016.
- 880 29. Bhavnani SK, Chen T, Ayyaswamy A, Visweswaran S, Bellala G, Rohit D, et al. Enabling Comprehension of  
881 Patient Subgroups and Characteristics in Large Bipartite Networks: Implications for Precision Medicine.  
882 *Proceedings of AMIA Joint Summits on Translational Science*. 2017:21-9. Epub 2017/08/18. PubMed PMID:  
883 28815099; PubMed Central PMCID: PMCPCMC5543384.
- 884 30. Bhavnani SK, Eichinger F, Martini S, Saxman P, Jagadish HV, Kretzler M. Network analysis of genes regulated  
885 in renal diseases: implications for a molecular-based classification. *BMC bioinformatics*. 2009;10 Suppl 9:S3.  
886 Epub 2009/09/26. doi: 10.1186/1471-2105-10-s9-s3. PubMed PMID: 19761573; PubMed Central PMCID:  
887 PMCPCMC2745690.
- 888 31. Bhavnani SK, Bellala G, Ganesan A, Krishna R, Saxman P, Scott C, et al. The nested structure of cancer  
889 symptoms. Implications for analyzing co-occurrence and managing symptoms. *Methods of information in  
890 medicine*. 2010;49(6):581-91. Epub 2010/11/19. doi: 10.3414/me09-01-0083. PubMed PMID: 21085743;  
891 PubMed Central PMCID: PMCPCMC3647463.
- 892 32. Bhavnani SK, Ganesan A, Hall T, Maslowski E, Eichinger F, Martini S, et al. Discovering hidden relationships  
893 between renal diseases and regulated genes through 3D network visualizations. *BMC research notes*.  
894 2010;3:296. Epub 2010/11/13. doi: 10.1186/1756-0500-3-296. PubMed PMID: 21070623; PubMed Central  
895 PMCID: PMCPCMC3001742.
- 896 33. Bhavnani SK, Victor S, Calhoun WJ, Busse WW, Bleecker E, Castro M, et al. How cytokines co-occur across  
897 asthma patients: from bipartite network analysis to a molecular-based classification. *Journal of biomedical  
898 informatics*. 2011;44 Suppl 1:S24-30. Epub 2011/10/12. doi: 10.1016/j.jbi.2011.09.006. PubMed PMID:  
899 21986291; PubMed Central PMCID: PMCPCMC3277832.
- 900 34. Bhavnani SK, Bellala G, Victor S, Bassler KE, Visweswaran S. The role of complementary bipartite visual  
901 analytical representations in the analysis of SNPs: a case study in ancestral informative markers. *Journal of  
902 the American Medical Informatics Association: JAMIA*. 2012;19(e1):e5-e12. Epub 2012/06/22. doi:  
903 10.1136/amiajnl-2011-000745. PubMed PMID: 22718038; PubMed Central PMCID: PMCPCMC3392853.

- 904 35. Bhavnani SK, Dang B, Bellala G, Divekar R, Visweswaran S, Brasier AR, et al. Unlocking proteomic  
905 heterogeneity in complex diseases through visual analytics. *Proteomics*. 2015;15(8):1405-18. Epub  
906 2015/02/17. doi: 10.1002/pmic.201400451. PubMed PMID: 25684269; PubMed Central PMCID:  
907 PMCPMC4471338.
- 908 36. Bhavnani SK, Dang B, Kilaru V, Caro M, Visweswaran S, Saade G, et al. Methylation differences reveal  
909 heterogeneity in preterm pathophysiology: results from bipartite network analyses. *Journal of perinatal  
910 medicine*. 2018;46(5):509-21. Epub 2017/07/01. doi: 10.1515/jpm-2017-0126. PubMed PMID: 28665803;  
911 PubMed Central PMCID: PMCPMC5971156.
- 912 37. Raudenbush SWBAS. Hierarchical linear models: applications and data analysis methods. Thousand Oaks:  
913 Sage Publications; 2002.
- 914 38. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among Patients in the Medicare Fee-for-Service  
915 Program. *N Engl J Med*. 2009;360(14):1418-28. doi: doi:10.1056/NEJMs0803563. PubMed PMID:  
916 19339721.
- 917 39. Report to Congress: Promoting Greater Efficiency in Medicare. Washington D.C.: MedPac (Medical Payment  
918 Advisory Commission); 2007.
- 919 40. Ashton CM, Del Junco DJ, Soucek J, Wray NP, Mansyur CL. The association between the quality of inpatient  
920 care and early readmission: a meta-analysis of the evidence. *Medical care*. 1997;35(10):1044-59. Epub  
921 1997/10/24. PubMed PMID: 9338530.
- 922 41. Yale New Haven Health Services Corporation/Center for Outcomes Research & Evaluation. 2015 Condition-  
923 specific measures updates and specifications report: Hospital-level 30-day risk-standardized readmission  
924 measures on acute myocardial infarction, heart failure, pneumonia, chronic obstructive pulmonary disease,  
925 and stroke. A report prepared for the Centers for Medicare & Medicaid Services (CMS) 2015 [April 20, 2015].  
926 Available from: [http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-  
927 Instruments/HospitalQualityInits/Measure-Methodology.html](http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html).
- 928 42. Keenan PS, Normand SL, Lin Z, Drye EE, Bhat KR, Ross JS, et al. An administrative claims measure suitable for  
929 profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart  
930 failure. *Circ Cardiovasc Qual Outcomes*. 2008;1(1):29-37. Epub 2008/09/01. doi:  
931 10.1161/circoutcomes.108.802686. PubMed PMID: 20031785.
- 932 43. Yale New Haven Health Services Corporation/Center for Outcomes Research & Evaluation. 2015 Procedure-  
933 specific readmission measures updates and specifications report: Elective primary total hip arthroplasty  
934 and/or total knee arthroplasty, and isolated coronary artery bypass graft surgery. A report prepared for the  
935 Centers for Medicare & Medicaid Services (CMS) 2015 [April 20, 2015]. Available from:  
936 [http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-  
937 Instruments/HospitalQualityInits/Measure-Methodology.html](http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html).
- 938 44. Lochner KA, Cox CS. Prevalence of Multiple Chronic Conditions Among Medicare Beneficiaries, United States,  
939 2010. *Prev Chronic Dis*. 2013;10:E61. doi: 10.5888/pcd10.120137.
- 940 45. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, et al. Renal function,  
941 neurohormonal activation, and survival in patients with chronic heart failure. *Circulation*. 2000;102(2):203-  
942 10. Epub 2000/07/13. PubMed PMID: 10889132.
- 943 46. Sharif R, Parekh TM, Pierson KS, Kuo YF, Sharma G. Predictors of early readmission among patients 40 to 64  
944 years of age hospitalized for chronic obstructive pulmonary disease. *Ann Am Thorac Soc*. 2014;11(5):685-  
945 94. Epub 2014/05/03. doi: 10.1513/AnnalsATS.201310-358OC. PubMed PMID: 24784958; PubMed Central  
946 PMCID: PMCPMC4225809.
- 947 47. Grosso LM, Curtis JP, Lin Z, Geary LL, Vellanky S, Oladele C, et al. Hospital-level 30-Day All-Cause Risk-  
948 Standardized Readmission Rate Following Elective Primary Total Hip Arthroplasty (THA) And/Or Total Knee  
949 Arthroplasty (TKA). Yale New Haven Health Services Corporation/Center for Outcomes Research &  
950 Evaluation, 2012.
- 951 48. Medicare Payment Advisory Commission (MedPAC). Report to the Congress: Medicare and the Health Care  
952 Delivery System. Chapter 3. Approaches to Bundle Payment for Post-Acute Care Washington, DC2013  
953 [updated June]. 57-88]. Available from:  
954 [http://www.medpac.gov/documents/reports/jun13\\_ch03.pdf?sfvrsn=0](http://www.medpac.gov/documents/reports/jun13_ch03.pdf?sfvrsn=0).



- 955 49. Evaluation YNHHSccfOR. Procedure-Specific Measures Updates and Specifications Report Hospital-Level 30-  
956 Day Risk-Standardized Readmission Measures. A report prepared for the Centers for Medicare & Medicaid  
957 Services (CMS) 2017 [June 1, 2017]. Available from: [https://www.cms.gov/Medicare/Quality-Initiatives-  
958 Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html](https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html).
- 959 50. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in  
960 longitudinal studies: development and validation. *J Chronic Dis*. 1987;40(5):373-83. PubMed PMID: 3558716.
- 961 51. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data.  
962 *Medical care*. 1998;36(1):8-27. PubMed PMID: 9431328.
- 963 52. Yale New Haven Health Services Corporation/Center for Outcomes Research & Evaluation. 2017 Condition-  
964 specific measures updates and specifications report: Hospital-level 30-day risk-standardized readmission  
965 measures on acute myocardial infarction, heart failure, pneumonia, chronic obstructive pulmonary disease,  
966 and stroke. A report prepared for the Centers for Medicare & Medicaid Services (CMS) 2017 [June 1, 2017].  
967 Available from: [https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-  
968 Instruments/HospitalQualityInits/Measure-Methodology.html](https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html).
- 969 53. SAS. Using SAS® to Perform Individual Matching in Design of Case-Control Studies 2010 [cited 2020 May,  
970 5th]. Available from: <https://support.sas.com/resources/papers/proceedings10/061-2010.pdf>.
- 971 54. Islam MM, Valderas JM, Yen L, Dawda P, Jowsey T, McRae IS. Multimorbidity and comorbidity of chronic  
972 diseases among the senior Australians: prevalence and patterns. *PloS one*. 2014;9(1):e83783. Epub  
973 2014/01/15. doi: 10.1371/journal.pone.0083783. PubMed PMID: 24421905; PubMed Central PMCID:  
974 PMCpMc3885451.
- 975 55. Treviño S, Nyberg A, Del Genio CI, Bassler KE. Fast and accurate determination of modularity and its effect  
976 size. *Journal of Statistical Mechanics: Theory and Experiment*. 2015;2015(2):P02003. doi: 10.1088/1742-  
977 5468/2015/02/p02003.
- 978 56. Chauhan R, Ravi J, Datta P, Chen T, Schnappinger D, Bassler KE, et al. Reconstruction and topological  
979 characterization of the sigma factor regulatory network of Mycobacterium tuberculosis. *Nature*  
980 *communications*. 2016;7:11062. Epub 2016/04/01. doi: 10.1038/ncomms11062. PubMed PMID: 27029515;  
981 PubMed Central PMCID: PMCPMC4821874.
- 982 57. Rand WM. Objective Criteria for the Evaluation of Clustering Methods. *Journal of the American Statistical*  
983 *Association*. 1971;66(336):846-50. doi: 10.2307/2284239.
- 984 58. Fruchterman T, Reingold E. Graph Drawing by Force-Directed Placement. *Software – Practice & Experience*.  
985 1991;21(11):1129–64.
- 986 59. Bennett TD, Moffitt RA, Hajagos JG, Amor B, Anand A, Bissell MM, et al. The National COVID Cohort  
987 Collaborative: Clinical Characterization and Early Severity Prediction. medRxiv. 2021. Epub 2021/01/21. doi:  
988 10.1101/2021.01.12.21249511. PubMed PMID: 33469592; PubMed Central PMCID: PMCPMC7814838 Amin  
989 Manna, and Nabeel Qureshi: employee of Palantir Technologies; Brian T. Garibaldi: Member of the FDA  
990 Pulmonary-Allergy Drugs Advisory Committee (PADAC); Matvey B. Palchuk: employee of TriNetX; Kristin  
991 Kostka: employee of IQVIA Inc.; Julie A. McMurry: and Melissa A. Haendel Cofounders of Pryzm Health; Chris  
992 P. Austin and Ken R. Gersing, employees of the National Institutes of Health. No conflicts of interest reported  
993 for all other authors.
- 994 60. Topaloglu U, Palchuk MB. Using a Federated Network of Real-World Data to Optimize Clinical Trials  
995 Operations. *JCO clinical cancer informatics*. 2018;2:1-10. Epub 2019/01/18. doi: 10.1200/cci.17.00067.  
996 PubMed PMID: 30652541; PubMed Central PMCID: PMCPMC6816049.
- 997 61. Dogrusoz U, Karacelik A, Safarli I, Balci H, Dervishi L, Siper MC. Efficient methods and readily customizable  
998 libraries for managing complexity of large networks. *PloS one*. 2018;13(5):e0197238. Epub 2018/05/31. doi:  
999 10.1371/journal.pone.0197238. PubMed PMID: 29813080; PubMed Central PMCID: PMCPMC5973603 the  
1000 following competing interests: I.S., H.B., and L.D. were supported through Google Summer of Code for  
1001 implementing some of the algorithms in this work as part of open source software projects. Others have no  
1002 competing interests. This does not alter the authors' adherence to PLOS ONE policies on sharing data and  
1003 materials.

- 1004 62. Wu J, Zhu F, Liu X, Yu H. An Information-Theoretic Framework for Evaluating Edge Bundling Visualization.  
1005 Entropy (Basel, Switzerland). 2018;20(9). Epub 2018/08/21. doi: 10.3390/e20090625. PubMed PMID:  
1006 33265714; PubMed Central PMCID: PMC7513140.
- 1007 63. Dhillon IS, Sra S. Generalized nonnegative matrix approximations with Bregman divergences. Proceedings  
1008 of the 18th International Conference on Neural Information Processing Systems; Vancouver, British  
1009 Columbia, Canada. 2976284: MIT Press; 2005. p. 283-90.
- 1010 64. Dilsizian ME, Siegel EL. Machine Meets Biology: a Primer on Artificial Intelligence in Cardiology and Cardiac  
1011 Imaging. Current cardiology reports. 2018;20(12):139. Epub 2018/10/20. doi: 10.1007/s11886-018-1074-8.  
1012 PubMed PMID: 30334108.
- 1013 65. Bhavnani SK, Visweswaran S, Divekar R, Brasier AR. Towards Team-Centered Informatics: Accelerating  
1014 Innovation in Multidisciplinary Scientific Teams Through Visual Analytics. The Journal of Applied Behavioral  
1015 Science. 2018:0021886318794606. doi: 10.1177/0021886318794606.
- 1016 66. Wooten KC, Calhoun WJ, Bhavnani S, Rose RM, Ameredes B, Brasier AR. Evolution of Multidisciplinary  
1017 Translational Teams (MTTs): Insights for Accelerating Translational Innovations. Clinical and translational  
1018 science. 2015;8(5):542-52. Epub 2015/03/25. doi: 10.1111/cts.12266. PubMed PMID: 25801998; PubMed  
1019 Central PMCID: PMC4575623.
- 1020